scholarly journals A multivariable Mendelian randomization analysis disentangling the causal relations between abdominal obesity, non-alcoholic fatty liver disease and cardiometabolic diseases

2021 ◽  
Author(s):  
William Pelletier ◽  
Eloi Gagnon ◽  
Emilie Gobeil ◽  
Jerome Bourgault ◽  
Hasanga D Manikpurage ◽  
...  
Keyword(s):  
Liver Disease ◽  
Waist Circumference ◽  
Fatty Liver ◽  
Abdominal Obesity ◽  
Fatty Liver Disease ◽  
Mendelian Randomization ◽  
Summary Statistics ◽  
Alcoholic Fatty Liver ◽  
Cardiometabolic Diseases ◽  
Alcoholic Fatty Liver Disease

Background: Observational studies have linked obesity and especially abdominal obesity to non-alcoholic fatty liver disease (NAFLD). These traits are also associated with type 2 diabetes (T2D) and coronary artery disease (CAD) but the causal factor(s) underlying these associations remain unexplored. Methods: We used a multivariable Mendelian randomization (MVMR) study design to determine whether obesity (defined using body mass index [BMI]) and abdominal obesity (defined using waist circumference) were causally associated with NAFLD using publicly available genome-wide association study (GWAS) summary statistics of the UK Biobank (n>450,000) and a GWAS meta-analysis of NAFLD (8434 cases and 770,180 control). A MVMR study design was also used to determine the respective causal contributions of waist circumference and NAFLD to T2D and CAD using additional GWAS summary statistics of the DIAGRAM (74,124 cases and 824,006 controls) and CARDIoGRAMplusC4D (122,733 cases and 424,528 controls) consortia. Results: In univariable Mendelian randomization analyses, both BMI and waist circumference were associated with NAFLD. NAFLD was not associated with obesity or abdominal obesity. In MVMR analyses, waist circumference was associated with NAFLD when accounting for BMI (OR per 1-standard deviation increase = 2.56 95% CI: 1.39-4.69, p=2.4e-03) and BMI was not associated with NAFLD when accounting for waist circumference (0.81 95% CI: 0.5-1.31, p =3.9e-01). In MVMR analyses accounting for NAFLD, waist circumference remained strongly associated with both T2D (3.25 95% CI: 2.87-3.68, p=5.1e-77) and CAD (1.62 95% CI: 1.48-1.76, p=6.5e-28). Conclusions: These results identified abdominal obesity as a strong, independent and causal contributor to NAFLD, T2D and CAD, suggesting that interventions targeting abdominal obesity rather than body weight per se should be prioritized for the prevention and management of cardiometabolic diseases.

scholarly journals The Risk of Abdominal Obesity according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men

2016 ◽  
Vol 31 (3) ◽  
pp. 410 ◽  
Author(s):  
Sung Keun Park ◽  
Jae-Hong Ryoo ◽  
Joong-Myung Choi ◽  
Min Woo Seo ◽  
Chung Min Park
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Abdominal Obesity ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Association of Non-Alcoholic Fatty Liver Disease with Metabolic Syndrome: A Single Center Study

2022 ◽  
Vol 8 (1) ◽  
pp. 310-317
Author(s):  
Debasish Dutta
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Liver Disease ◽  
Waist Circumference ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
College Hospital ◽  
Alcoholic Fatty Liver ◽  
Grade Ii ◽  
Alcoholic Fatty Liver Disease

Background: NAFLD is a condition defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver (> 5% of hepatocytes histologically). Non-alcoholic fatty liver disease is increasingly being recognized as a major cause of liver-related morbidity and mortality among 15-40% of the general population. Aim of the study: To evaluate the clinical profile of patients with non-alcoholic fatty liver disease and its association with metabolic syndrome.Methods:The present cross-sectional, retro-spective study was conducted as outdoor patient basis in the Department of Medicine, Jashore medical college hospital & a private diagnostic centre, Jashore.. A total of 74 cases were included for the study. All patients in the study underwent routine investigations including complete blood counts, blood sugar, liver function tests, HBsAg, anti-HCV, lipid profile andUSG of whole abdomen. The data was collected during OPD treatment and was recorded in predesigned and pretested proforma and analyzed.Results:Mean age of the patient was 53.70±7.22 years. On physical examination findings showed the mean BMI was 27.6±4.39 kg/m2, mean waist circumference was 74.22±7.44 cm. Mean diastolic blood pressure (mm Hg) was 92.87±6.25 and mean systolic blood pressure (mm Hg) 132.0±18.17. Maximum 52% patients had triglycerides >150 mg/dl while low serum HDL level was seen in 37% patients and increased waist circumference was found in 32% patients. Altered ALT ≥41 IU was observed in 10 (62.50%) of Grade II of patients with NAFLD with metabolic syndrome. Central obesity was observed in 12 (75.00%) of Grade II patients with NAFLD with metabolic syndrome. While 14 (87.50%) Grade II of patients with NAFLD with metabolic syndrome showed impaired fasting glucose (>110 mg/dl). Hypertriglyceridemia (>150 mg/dl) in 12 (70.58%) seen in Grade I of patients with NAFLD without metabolic syndrome.Conclusion:Higher prevalence of all the components of metabolic syndrome in cases of NAFLD was observed. It can be concluded that symptoms and signs of NAFLD are non-specific and occur later in the course of the disease hence the physician should have a high index of suspicion in order to detect NAFLD early in the course of the disease.

scholarly journals Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy

2019 ◽  
Vol 91 (2) ◽  
pp. 109-117 ◽  
Author(s):  
M V Maevskaya ◽  
V T Ivashkin ◽  
K V Ivashkin ◽  
V D Lunkov ◽  
E O Liusina ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Complex Treatment ◽  
Metabolic Complications ◽  
Alcoholic Fatty Liver ◽  
Cardiometabolic Diseases ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

The article presents an update of the role of non-alcoholic fatty liver disease (NAFLD) in cardiometabolic diseases and events: arterial hypertension and components of the metabolic syndrome. A review of NAFLD modern pharmacotherapy has been conducted. Particular attention is paid to the place of ursodeoxycholic acid in the complex treatment of NAFLD.

Sign in / Sign up

Export Citation Format

Share Document